Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm.

Vander Velde, Robert; Shaffer, Sydney; Marusyk, Andriy

Vander Velde, Robert; Shaffer, Sydney; Marusyk, Andriy.

Afiliación

Vander Velde R; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Shaffer S; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Bioengineering, University of Pennsylvania, Philadelphia, PA, USA.
Marusyk A; Department of Cancer Physiology, H Lee Moffitt Cancer Centre and Research Institute, Tampa, FL, USA. Electronic address: andriy.marusyk@moffitt.org.

Trends Cancer ; 8(6): 456-466, 2022 06.

Article en En | MEDLINE | ID: mdl-35307314

Asunto(s)

Resistencia a Antineoplásicos; Epigénesis Genética; Neoplasias; Selección Genética; Resistencia a Antineoplásicos/genética; Humanos; Mutación; Neoplasias/tratamiento farmacológico; Fenotipo

Palabras clave

Darwinian evolution; acquired resistance; cellular reprogramming; targeted therapy

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Selección Genética / Resistencia a Antineoplásicos / Epigénesis Genética / Neoplasias Límite: Humans Idioma: En Revista: Trends Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google